石藥集團(01093.HK):高血壓和冠心病治療藥物“硝苯地平控釋片”獲藥品註冊批件
格隆匯4月22日丨石藥集團(01093.HK)發佈公吿,公司附屬公司石藥集團歐意藥業有限公司開發的“硝苯地平控釋片(30 mg)”已獲得中國國家藥品監督管理局頒發的藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。
硝苯地平是第一個二氫吡啶類鈣拮抗劑,主要用於高血壓和冠心病(慢性穩定性心絞痛即勞累性心絞痛)的治療。該產品為高端控釋製劑,採用推拉式滲透泵原理,使藥物以零級速率釋放,能有效平穩血藥濃度,改善普通製劑的副作用。該產品的獲批將進一步豐富集團於心腦血管疾病領域的產品線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.